Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Portable Ultrasound Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
Factors that are responsible for the growth of the portable ultrasound devices market include increasing spectrum of applications of the portable ultrasound, increasing advancements in technology, and the growing prevalence of chronic diseases.
The introduction of portable ultrasound devices has a variety of applications in many emerging fields, like emergency medicine, critical care medicine, and musculoskeletal. Portable ultrasound devices are used for easy access to ultrasound when limited space is there. Currently, these devices are being used in the major areas of diseases, such as cardiology, radiology endocrinology and gynecology. Since there is a rising need for ambulatory services across developing as well as developed countries, the demand for portable ultrasound devices is increasing, which is leading to the growth of the market.
Scope of the Report
Portable ultrasound systems are small devices compared to traditional ultrasound systems. These devices are lightweight and easy to handle.
Key Market Trends
Mobile Ultrasound Device is Expected to Grow with High CAGR
The mobile ultrasound device segment of the portable ultrasound devices market is expected to experience the fastest growth rate over the forecast period.
Mobile ultrasound devices are gaining attraction in the developing regions, due to the rising demand for ambulatory care. Although developed countries, like the United States, have a well-established market for handheld ultrasound devices, there is also a rising demand for mobile ultrasound devices. Due to its efficacy in providing mobile care, the segment is expected to grow rapidly over the forecast period.
North America Dominates the Market and Expected to Follow the Same Trend Over the Forecast Period
North America currently dominates the portable ultrasound devices market and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. This can be majorly attributed to the increasing incidences of chronic disorders, rising demand for advanced ultrasound systems, and the presence of the developed healthcare infrastructure.
Competitive Landscape
The portable ultrasound devices market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need of mobile health and the advancements in ultrasonography, few smaller players are entering the market and holding a substantial share. Some of the major players of the market are Fukuda Denshi, Hitachi Ltd, Koninklijke Philips NV, Canon Medical Systems Corporation, and Siemens Healthineers, among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Spectrum of Applications of Portable Ultrasound
4.2.2 Increasing Advancements in Technology
4.2.3 Increasing Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 High Cost of Portable Ultrasound Systems
4.3.2 Lack of Dedicated Training Programs by Companies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Device
5.1.1 Mobile Ultrasound Device
5.1.2 Handheld Ultrasound Device
5.2 By Area of Application
5.2.1 Traditional Areas
5.2.1.1 Radiology
5.2.1.2 Gynecology
5.2.1.3 Cardiology
5.2.1.4 Urology
5.2.1.5 Other Traditional Areas
5.2.2 Emerging Areas
5.2.2.1 Emergency Medicine
5.2.2.2 Anesthesiology
5.2.2.3 Critical Care Medicine
5.2.2.4 Musculoskeletal
5.2.3 By End User
5.2.3.1 Hospitals
5.2.3.2 Diagnostic Centers
5.2.3.3 Ambulatory Care Centers
5.2.3.4 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Fujifilm SonoSite Inc.
6.1.2 GE Healthcare
6.1.3 Hitachi Ltd
6.1.4 Shenzhen Mindray
6.1.5 Canon Medical Systems Corporation
6.1.6 Koninklijke Philips NV
6.1.7 Samsung Healthcare
6.1.8 Siemens Healthineers
6.1.9 Fukuda Denshi Co. Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type of Device
Mobile Ultrasound Device
Handheld Ultrasound Device
By Area of Application
Traditional Areas
Radiology
Gynecology
Cardiology
Urology
Other Traditional Areas
Emerging Areas
Emergency Medicine
Anesthesiology
Critical Care Medicine
Musculoskeletal
By End User
Hospitals
Diagnostic Centers
Ambulatory Care Centers
Other End Users
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Precision Medicine Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 07-06-2019
Market Overview
The global precision medicine market was valued at USD 48,554.1 million in 2018, and is estimated to be valued at USD 84,590.21 million in 2024, witnessing a CAGR of 9.7%. The key factors propelling the growth of this market are increasing online collaborative forums, increasing efforts to characterize genes, and advancements in cancer biology. The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type. Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.
The functional characterization of identified genomic mutations, coupled with comprehensive clinical data available in electronic health records, has the potential to provide compelling evidence to implicate novel disease and/or drug-associated mutations in phenotypically well-characterized patients. There have been increasing efforts made by both the government and private players to establish databases that contain information of characterized genes of a large population. Some countries are establishing a national repository of genetic information to accelerate the research in precision medicine. Methods, such as meta-analysis, transcriptome data analysis, and RNA-seq data analysis, are employed to characterize genes, generally.
Scope of the Report
Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention. The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment, and lifestyle, for each person, while developing drugs and vaccines.
Key Market Trends
Oncology is Expected to hold the Highest Market Share in the Application Segment
In the application segment of the precision medicine market, oncology is believed to have the largest market size and is expected to witness a CAGR of 10.3%, during the forecast period.
Precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. As per the data reported in clinicaltrials.gov, the United States and some European countries are the major hubs for conducting and recruiting patient pool for precision medicine applications in oncology, globally. The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for precision medicine, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Former President Barack Obama, in 2015, unveiled the Precision Medicine Initiative (PMI), a bold new enterprise to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into every-day clinical practice.
The Precision Medicine Initiative also includes ongoing efforts through the Department of Veteran’s Affairs (VA), which has enrolled over 450,000 veterans in the Million Veteran Program (MVP), a participant-driven research cohort. The Food and Drug Administration (FDA), the Office of the National Coordinator for Health IT, and the Office for Civil Rights announced in February 2016 that they will build research and data capacity, technical tools, and policies to accelerate precision medicine, thereby, boosting the precision medicine market in the country.
Competitive Landscape
The precision medicine market is highly competitive and consists of several major players, along with a number of smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with affordable prices. Companies, like Medtronic PLC, Pfizer Inc., Novartis AG, Qiagen, and Teva Pharmaceuticals, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Online Collaborative Forums
4.2.2 Increasing Efforts to Characterize Genes
4.2.3 Advancement in Cancer Biology
4.3 Market Restraints
4.3.1 Perils of Data Sharing
4.3.2 Shift From Treatment-based To Preventive Healthcare
4.3.3 Declining Trends in FDA Pharmacotherapy Approval Rate
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Big Data Analytics
5.1.2 Bioinformatics
5.1.3 Gene Sequencing
5.1.4 Drug Discovery
5.1.5 Companion Diagnostics
5.1.6 Other Technologies
5.2 By Application
5.2.1 Oncology
5.2.2 CNS
5.2.3 Immunology
5.2.4 Respiratory
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biocrates Life Sciences AG
6.1.2 Nanostring Technologies
6.1.3 Intomics
6.1.4 Pfizer Inc.
6.1.5 Eagle Genomics Ltd
6.1.6 Teva Pharmaceutical Industries Ltd
6.1.7 Laboratory Corporation Of America Holdings
6.1.8 Medtronic
6.1.9 Novartis AG
6.1.10 Qiagen NV
6.1.11 Quest Diagnostics Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Big Data Analytics
Bioinformatics
Gene Sequencing
Drug Discovery
Companion Diagnostics
Other Technologies
By Application
Oncology
CNS
Immunology
Respiratory
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 10-06-2019
Market Overview
The global preventive vaccines market is currently recording a CAGR of 6.18%. The preventive vaccines market has attained maturity in some of the disease segments, like polio, while for some diseases, it is yet to establish itself in the market. In spite of these differences in each segment, the market is continuously experiencing growth, due to the varying degrees of increase of the demand for vaccination for separate diseases over time. The growth of the global preventive vaccines market is due to the increasing prevalence of infectious diseases, innovative technology in vaccine development, increased funding from government and international organizations, and increasing awareness on preventive care.
Infectious diseases are considered to be the world’s greatest killers that pose some of the most significant health and security threats faced by the global community. Various infectious diseases are among the world’s leading causes of death. Scientists from every country are currently performing research, sharing information, building laboratory capacity in underdeveloped countries, and creating global surveillance networks in order to prevent and control their spread through preventive vaccinations. However, healthcare costs are rising astronomically and the trends are leaning toward prevention. The cost of vaccination has gone from a single digit to even triple digits few times over the past two decades, thus creating serious dilemmas for doctors and their patients, as well as straining public health budgets.
Scope of the Report
As per the scope of this report, a preventative vaccine is administered to a person who is free of the targeted infection, in order to support the body’s immune system against future infections. These vaccines consist of attenuated or killed microbes, or microbial DNA. When administered, the immune system triggers a response that produces antibodies.
Key Market Trends
Live/Attenuated Vaccines Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period
Live/attenuated vaccines contain weakened versions of living microbes, making them ineffective to cause diseases. These vaccines produce a similar, yet weakened reaction, compared to that of natural infections. The immune system generates strong cellular and antibody responses that often confer lifelong immunity, with only one or two doses. The live/attenuated vaccines need to be refrigerated to stay potent. In addition, if the vaccine needs to be shipped overseas and stored by healthcare workers, in developing countries that lack widespread refrigeration, a live vaccine may not be the best choice. Live/attenuated vaccines for certain viruses are relatively easy to create. Vaccines against measles, mumps, and chickenpox, among others, are designed using this method. Pertaining to the ease of manufacturing, and the ability to generate strong immune responses to the market for live/attenuated vaccines, a steady growth rate is expected during the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America holds the largest share in the market, with the United States being the largest contributor to its revenue. In the United States, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee for Immunization Practices (ACIP) routinely publishes recommendations for adult and childhood vaccination. The United States has one of the leading healthcare systems in the world and the vaccination coverage, in terms of vaccine inclusion, is at par with the WHO guidelines. Thus, the preventive vaccine market in the region is expected to show moderate growth over the forecast period.
Competitive Landscape
Some of the key players in the market are AstraZeneca PLC, Emergent BioSolutions Inc., Daiichi Sankyo Co. Ltd, GlaxoSmithKline PLC, and Johnson & Johnson, among others. These companies are also focusing on innovations, and are spending majorly in R&D in order to lead the global preventive vaccines market, thereby increasing competition among them.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Infectious Diseases
4.2.2 Innovative Technology in Vaccine Development
4.2.3 Increased Funding from Government and International Organizations
4.2.4 Growing Awareness about Preventive Care
4.3 Market Restraints
4.3.1 Risk of Adverse Effects
4.3.2 Huge Capital Expenditures
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Vaccine Type
5.1.1 Live/Attenuated Vaccines
5.1.2 Inactivated Vaccines
5.1.3 Subunit Vaccines
5.1.4 Toxoid Vaccines
5.1.5 Conjugate Vaccines
5.1.6 Recombinant Vector Vaccines
5.1.7 DNA Vaccines
5.2 By Disease Type
5.2.1 Pneumococcal
5.2.2 Poliovirus
5.2.3 Hepatitis
5.2.4 Influenza
5.2.5 Measles, Mumps, and Rubella (MMR)
5.2.6 Varicella
5.2.7 Human Papilloma Virus
5.2.8 Other Disease Types
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Emergent BioSolutions Inc.
6.1.3 Daiichi Sankyo Co. Ltd
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 Merck & Co.
6.1.7 Novavax Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi SA
6.1.10 Takeda Pharmaceutical Co. Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Vaccine Type
Live/Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
Conjugate Vaccines
Recombinant Vector Vaccines
DNA Vaccines
By Disease Type
Pneumococcal
Poliovirus
Hepatitis
Influenza
Measles, Mumps, and Rubella (MMR)
Varicella
Human Papilloma Virus
Other Disease Types
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Protein Engineering Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the global protein engineering market include the increasing prevalence of protein deficient diseases, increase in adoption of protein drugs over non-protein drugs, increased demand for alternatives to chemical processes, and rising government funding for protein engineering.
Protein-energy malnutrition (PEM) is increasing in the rural areas of emerging economies. It refers to a group of disorders that includes marasmus, kwashiorkor and intermediate states of marasmus-kwashiorkor. Therefore the prevalence of kwashiorkor varies from geography to geography. It is rare in the United States; however most affected regions include Southeast Asia, Central America, Congo, Puerto Rico, Jamaica, and South Africa. Thus, the increasing prevalence of protein-deficient diseases is driving the overall market.
There is a rising number of government initiatives, such as funding R&D for protein engineering and awareness programs, which have influenced the healthcare industry. The government is thus proactively investing in many of the research studies. For instance, Protein Technologies Ltd (PTL) has received funding from the UK government’s Technology Strategy Board (now Innovate UK) for its innovative research in protein engineering. Hence the increasing number of government initiatives for the efficient protein engineering research helps in driving the overall growth of the market.
Protein engineering also holds immense opportunity in the agrochemical industry as engineering in proteins may lead to the generation of enzymes with improved function that may increase the crop yield or facilitate the biofuel production. It is also likely to play an important role as a tool to attain increased crop yield needed to meet future demands.
Scope of the Report
As per the scope of the report, protein engineering is the manipulation of the structures of proteins to produce the desired properties, or the synthesis of proteins with particular structures. It is the process by which novel proteins with desired properties are developed, and has grown enormously since past three decades. In the past years, protein engineers have successfully generated a wide range of proteins tailored to specific health, industry, medicine, research, and biotechnology applications.
Key Market Trends
Monoclonal Antibodies by Protein Type is the Largest Segment that is Expected to Grow Fastest During the Forecast Period
Monoclonal antibodies are anticipated to hold the largest market share in the future, owing to their high adoption for numerous therapies, such as cancer and autoimmune diseases. They also have tremendous applications in the fields of therapeutics, diagnostics, and targeted drug delivery systems, for infectious diseases caused by viruses, bacteria, and protozoa, as well as for cancer, and metabolic and hormonal disorders. Hence, recombinant deoxyribonucleic acid technology through genetic engineering has successfully led to the possibility of reconstruction of monoclonal antibodies, thus fueling the growth of the segment.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific market is expected to witness the fastest CAGR during the forecast period, owing to the growing presence of contract research organizations, rising healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards across this region. Growing demand for personalized medicine and strong R&D investments in proteomics-based drug discovery projects are also supplementing the growth of the protein engineering market.
Competitive Landscape
The global protein engineering market players are highly focused on strategies, such as mergers and acquisitions, new product development initiatives, and geographical expansion. As the cost of R&D is high and requires high-end infrastructure, most of the pharmaceutical and biotechnology companies are moving toward CROs. Most of the players in the CRO industry are joining forces in order to create a market position.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Protein-deficient Diseases
4.2.2 Increased Demand for Alternatives to Chemical Processes
4.2.3 Increase in Adoption of Protein Drugs over Non-protein Drugs
4.2.4 Rising Government Funding for Protein Engineering
4.3 Market Restraints
4.3.1 Lack of Experts to Strategize the Process
4.3.2 High Costs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Modified Enzymes
5.1.2 Insulin
5.1.3 Monoclonal Antibodies
5.1.4 Coagulation Factors (Blood factors + Tissue plasminogen)
5.1.5 Vaccines
5.1.6 Growth Factors (Hormones + Cytokine)
5.1.7 Other Product Types
5.2 By Technology
5.2.1 Irrational Protein Design
5.2.2 Rational Protein Design
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic Institutions
5.3.3 Contract Research Organizations (CROs)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Amgen Inc.
6.1.3 Bruker Corporation
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Eli Lilly and Company
6.1.6 Merck KGaA
6.1.7 Novo Nordisk AS
6.1.8 PerkinElmer Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Waters Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Modified Enzymes
Insulin
Monoclonal Antibodies
Coagulation Factors (Blood factors + Tissue plasminogen)
Vaccines
Growth Factors (Hormones + Cytokine)
Other Product Types
By Technology
Irrational Protein Design
Rational Protein Design
By End User
Pharmaceutical and Biotechnology Companies
Academic Institutions
Contract Research Organizations (CROs)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Proton Pump Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 12-06-2019
Market Overview
The major factors for the growth of the proton pump inhibitors market include the increasing prevalence of gastroesophageal reflux disease (GERD) and the rising acceptance of novel drug delivery systems.
Gastroesophageal reflux disease is a chronic condition, where the stomach content comes back up into the esophagus resulting in either symptoms or complications. The most frequently reported symptoms of GERD are heartburn, a burning discomfort that begins behind the breastbone and radiates to the neck and throat, and acid regurgitation, which is characterized as a bitter, sour-tasting fluid.
In addition to the increase in prevalence, people with risk factors, such as obesity, tobacco use, and others, are also increasing in almost every part of the world. Obesity, which is the major risk factor of GERD, is increasing rapidly in developed countries, such as the United States, the United Kingdom, and others. The increasing prevalence of GERD, along with the growing risk factor population, is likely to lead to the growth in the demand for proton pump inhibitors, which in turn, will drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.
Scope of the Report
As per the scope of the report, proton pump inhibitors (PPIs) are a group of drugs, whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The market studied is further segmented on the basis of drug type and geography. The drug type segmentation includes OTC and prescription drugs.
Key Market Trends
Esomeprazole is Expected to Account for the Largest Market Share in Drug Type
Nexium is one among the leading revenue generating drugs globally, and it is used to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The drug was being sold as a prescriptive drug till before 28th March 2014, the date when FDA approved it as an OTC drug. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug in the near future. There are several benefits associated with OTC drugs, such as low price, enhanced accessibility, and no regular monitoring. As OTC drugs are sold without any prescription, the consumer need not go to any doctor for a prescription, which reduces the overall cost, and hence these drugs have the potential to increase their adoption rate. Accessibility is another vital factor for the consumption of any medicine, and better accessibility may definitely result in more revenue. However, OTC drugs have some disadvantages as well. As they can be purchased without any prescription, anyone can buy as many as they want and leave the scope for their overuse.
Additionally, there are several minor side effects, such as nausea, headaches, dry mouth, diarrhea, allergic reaction, and others, as well as some major side effects, such as kidney disease, dementia, and others associated with its use, which can affect the adoption rate, and hence can be the restraining factors for the growth of the market.
North America Accounted for the Largest Share in the Global Market
North America holds a major share in the proton pump inhibitors market and is expected to show a similar trend over the forecast period, without significant fluctuations. There is a rising prevalence of GERD in the United States, Canada, and Mexico. Furthermore, GERD affects up to 20% of adults in the United States, therefore making the disease an important concern. Proton pump inhibitors are the widely prescribed drugs, and increased PPI use has been observed in the US ambulatory settings. Furthermore, many firms are expected to spend heavily on promoting their brands. The widespread use of these has recently gained attention from the American Board of Internal Medicine’s campaign to promote the appropriate use of PPIs.
Competitive Landscape
The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market. The market players are focusing on acquiring the market share by focusing on aggressive advertisements and awareness programs among the patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
4.2.2 Rising Acceptance of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Use of Generic Products
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 OTC (Over-the-Counter) Drugs
5.1.1.1 Omeprazole
5.1.1.2 Lansoprazole
5.1.1.3 Esomeprazole
5.1.1.4 Other OTC Drugs
5.1.2 Prescription Drugs
5.1.2.1 Rabeprazole
5.1.2.2 Dexlansoprazole
5.1.2.3 Pantoprazole
5.1.2.4 Other Prescription Drugs
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer AG
6.1.3 Cadila Pharmaceuticals
6.1.4 Eli Lilly and Company
6.1.5 Eisai Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Santarus Inc.
6.1.10 Takeda Pharmaceuticals
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug Type
OTC (Over-the-Counter) Drugs
Omeprazole
Lansoprazole
Esomeprazole
Other OTC Drugs
Prescription Drugs
Rabeprazole
Dexlansoprazole
Pantoprazole
Other Prescription Drugs
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Rapid Diagnostic Kits Market Share – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the rapid diagnostic kits market include the increasing number of government initiatives for the diagnosis of infectious disease incidence, along with the rising need for fast detection of diseases, which are also contributing to the increasing demand for rapid diagnostic tests, across the world. In addition to this, the growth of government initiatives, such as awareness programs and funding research studies, has influenced the healthcare industry.
The government proactively invests in many of the research studies that include the diagnosis of infectious diseases. Thus, increasing government initiatives for the efficient diagnosis of infectious diseases help in driving the overall growth of the market studied.
The patients suffering from chronic diseases are found to have an increased risk of developing end-stage heart failure diseases. Therefore, the early identification and management of patients with chronic diseases are found to be important, in order to decrease morbidity and mortality. The early detection of diseases is possible with the screening programs targeting high-risk patients, such as patients with diabetes mellitus, hypertension, and elderly patients. Thus, there are several rapid diagnostic kits available for many chronic diseases, which diagnose the disease while it is asymptomatic, with no signs or symptoms.
The increase in home healthcare is driving the use of rapid diagnostics. This brings treatment and prevention care options to the patient’s home, thus, avoiding the long queue in hospitals. This saves the patients’ time and travel costs, thereby, driving the rapid diagnostics kits market.
Scope of the Report
As per the scope of the report, rapid medical diagnostic kits are used for detecting or diagnosing a wide range of infections, conditions, and diseases that the person might be suffering from. Moreover, these kits offer an accurate diagnosis for diseases, such as malaria, and conditions, such as diabetes and pregnancy. The rapidly growing medical diagnostics industry and high demand for the preventive management of infectious diseases caused by viruses and bacteria, worldwide, are some of the factors contributing to the growth of the rapid diagnostic kits market.
Key Market Trends
Veterinary testing is the segment under application that is expected to grow the fastest during the forecast period
There are several rapid diagnostic kits available in the market for veterinary testing. The range of different innovative technologies is available for real-time or rapid diagnosis of livestock diseases. The major advantage of rapid diagnostic kits is the cost, as costs less to test pets and other veterinary animals. All these benefits of rapid diagnostics kits are driving the veterinary segment of the market studied, which is expected to grow further during the forecast period.
The use of kits in home healthcare testing is also increasing every day, and no special skill is required to use the kits so patients can perform rapid diagnostic tests at home with the help of these kits, which are readily available in the market. Such benefits of the kits and the increasing adoption of the same by people are expected to help the market studied grow during the forecast period.
Asia-Pacific registered the fastest growth and is expected to follow the same trend over the forecast period
The Asia-Pacific region is predicted to witness high growth, due to the presence of a large base of patients with unmet medical needs in emerging economies, such as India and China. This is expected to help the Asia-Pacific rapid medical diagnostic kits market grow at the fastest rate during the forecast period. The increasing number of local manufacturers of RDT kits and the rising disease prevalence are propelling the need for rapid diagnostics, in turn, boosting the market growth over the forecast period.
Competitive Landscape
The rapid diagnostic kits market has leading companies, like Alere, BioMérieux, and Roche Diagnostics, among others. There are also several companies entering into the market. Also, several private companies are introducing innovative products to enter into the market. Various major companies based in the country have also contributed significantly to the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Government Initiatives for the Diagnosis of infectious Diseases
4.2.2 Rising Awareness Regarding Early Diagnosis among People
4.2.3 Shift in Technological and Commercial Environment
4.3 Market Restraints
4.3.1 Lack of Awareness Regarding Newer Rapid Diagnostic Tests
4.3.2 Failure to Eliminate the Need for Microscopy Diagnosis
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Flow Through
5.1.2 Solid Phase
5.1.3 Lateral Flow
5.1.4 Agglutination Assays
5.2 By Application
5.2.1 Hospitals and Clinical Testing
5.2.2 Home Testing
5.2.3 Veterinary Testing
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ACON Laboratories Inc.
6.1.2 Abbott Laboratories
6.1.3 Alfa Scientific Designs Inc.
6.1.4 Artron Laboratories Inc.
6.1.5 Becton, Dickinson and Company
6.1.6 BTNX Inc.
6.1.7 Meridian Bioscience Inc.
6.1.8 Creative Diagnostics
6.1.9 McKesson Medical-Surgical Inc.
6.1.10 F. Hoffmann-La Roche Ltd
6.1.11 Zoetis Inc.
6.1.12 BioMerieux
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Flow Through
Solid Phase
Lateral Flow
Agglutination Assays
By Application
Hospitals and Clinical Testing
Home Testing
Veterinary Testing
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America